Overview

• Biomea Fusion reports Q3 net loss of $16.4 mln, reduced from $32.8 mln last year

• Company raised $68 mln through public offerings, extending cash runway into 2027

• Icovamenib shows positive Phase II data, BMF-650 doses first patient in Phase I

Result Drivers

• ICOVAMENIB PROGRESS - Phase II results showed durable HbA1c reductions and favorable safety profile, supporting further clinical development

• BMF-650 STUDY INITIATION - First patient dosed in Phase I study for BMF-650, assessing weight loss potential in obesity

• COST REDUCTION - Significant decrease in R&D expenses contributed to reduced net loss

• R&D expenses were $14.4 million for the three months ended September 30, 2025, compared to $27.2 million for the same period in 2024

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Biomea Fusion Inc is $6.50, about 79.7% above its November 3 closing price of $1.32

Press Release: ID:nGNX3zFQY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)